Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia

Abstract Impaired platelet production is a mechanism of immune thrombocytopenia (ITP). Morphological abnormalities of megakaryocytes (MKs) are sometimes observed in this disease. Two studies have suggested an association between MK abnormalities and response to corticosteroids in primary ITP, but none have investigated this association for thrombopoietin-receptor agonists (TPO-RAs). This was the aim of this study. The source of population was the French CARMEN registry with prospective follow-up of adult patients with incident ITP. We included patients with primary ITP, treated by TPO-RA and with a bone marrow smear before initiating TPO-RA. MK abnormalities were categorized by the presence of dysplasia and by the stage of maturation. Among 451 patients screened, 38 were included in the analysis. There was no difference in the median percentage of dysplastic MKs between responders to TPO-RA (4.0%, 95% confidence interval – CI: 2.3–6.4) and non-responders (4.5%, 95% CI: 0.7–7.1). There was a slightly higher proportion of granular MKs (4.5%, 95% CI: 3–6) and basophilic MKs (30.1%, 95% CI: 21.9–39.1) in non-responders compared to responders (granular: 2.0%, 95% CI: 0–4.1; basophilic: 21.3%, 95% CI: 11.4–40.7). In conclusion, MK abnormalities were not associated with response achievement in ITP patients treated with TPO-RA in this series of 38 patients.

[1]  B. Bonnotte,et al.  Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments , 2021, HemaSphere.

[2]  D. Kuter The treatment of immune thrombocytopenia (ITP)—focus on thrombopoietin receptor agonists , 2021 .

[3]  J. Kelton,et al.  Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia. , 2020, Blood advances.

[4]  J. Semple,et al.  Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP) , 2020, Platelets.

[5]  S. Vesely,et al.  American Society of Hematology 2019 guidelines for immune thrombocytopenia. , 2019, Blood advances.

[6]  J. Bussel,et al.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia. , 2019, Blood advances.

[7]  Jingjing Zhu,et al.  Megakaryocyte Morphological Classification Based Predictive Model for Steroid Sensitivity in Primary Immune Thrombocytopenia , 2019, Blood.

[8]  J. Bussel,et al.  Response to thrombopoietic agents is related to on‐treatment bone marrow megakaryocyte morphology in patients with chronic immune thrombocytopenia , 2019, American journal of hematology.

[9]  J. Bussel,et al.  Thrombopoietin receptor agonists: ten years later , 2019, Haematologica.

[10]  S. Watson,et al.  Platelets – the second growth cycle , 2018, Platelets.

[11]  H. Al‐Samkari,et al.  Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia , 2018, American journal of hematology.

[12]  J. Bussel,et al.  Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. , 2017, Blood.

[13]  M. Lapeyre-Mestre,et al.  Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort , 2017, American journal of hematology.

[14]  J. Semple,et al.  Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) , 2017, Journal of clinical medicine.

[15]  P. Paudyal,et al.  Megakaryocytic alterations in thrombocytopenia: A bone marrow aspiration study , 2016 .

[16]  M. Lapeyre-Mestre,et al.  Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. , 2014, Blood.

[17]  Ashutosh Kumar,et al.  Megakaryocyte morphology and its impact in predicting response to steroid in immune thrombocytopenia , 2014, Platelets.

[18]  M. Lapeyre-Mestre,et al.  Pharmacoepidemiology of Immune Thrombocytopenia: protocols of FAITH and CARMEN studies. , 2014, Therapie.

[19]  Sompal Singh,et al.  Morphometric evaluation of megakaryocytes in bone marrow aspirates of immune-mediated thrombocytopenic purpura , 2013, Platelets.

[20]  J. Bussel,et al.  How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. , 2012, Blood.

[21]  M. Pai,et al.  Megakaryocytic alterations in thrombocytopenia: a bone marrow aspiration study. , 2009, Indian journal of pathology & microbiology.

[22]  E. L. Luning Prak,et al.  The ITP syndrome: pathogenic and clinical diversity. , 2009, Blood.

[23]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[24]  J. Bussel,et al.  Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[25]  J. George,et al.  Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial , 2008, The Lancet.

[26]  J. Bussel,et al.  The pathogenesis of immune thrombocytopaenic purpura , 2006, British journal of haematology.

[27]  E. Vellenga,et al.  Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. , 2004, Blood.